Abstract:

Men’s breast cancer is a disease that has different clinical-patological and immunohistochemical properties than female breast cancer and is rare compared to female breast cancer. Methods: From 2007 to 2019, the clinico-patological characteristics of male breast cancer patients followed and treated in the Department of Medical Oncology of the Dicle University Medical Faculty, the treatment they received and the treatment results were retrospective examined. The findings: 50 male patients diagnosed with invasive breast cancer were analyzed. The average age was 63.7 years (34-88) Thirty-four (88%) of the patients had a local advanced and metastatic disease. 38 (76%) of patients received mastectomy. The most common histological type was an invasive duktal carcinoma with a rate of 90%. In 40 patients (80%) there was an estrogen receptor, and in 41 (82) progesterone receptor positive. Overexpression of HER2 was observed in 11 (22%) patients. 30 (60%) of patients after curative surgery received adjuvant chemotherapy and 34 (68%) received adjuvant endocrine therapy. The media follow-up period was 54.5 months ( 1-299 months). In 15 of 39 patients in stage I-III (38 percent) the nickel developed while observed in remission. The median survival period was not achieved in patients with breast cancer of stages I and II, while the median survival period in patients of stages III and IV was 84 and 36 months, respectively. In one-variable and multi-variable analysis, only the axles were statistically significantly related to lymph nod retention, the size of the tumor and the stage of the disease with survival. The result: Our study has shown that in male breast cancer patients, acne lymph nod metastasis, the size of the tumor and the stage of the disease are important prognostic factors that predict survival.

Keywords: